NO2700405T3 - - Google Patents

Info

Publication number
NO2700405T3
NO2700405T3 NO13168599A NO13168599A NO2700405T3 NO 2700405 T3 NO2700405 T3 NO 2700405T3 NO 13168599 A NO13168599 A NO 13168599A NO 13168599 A NO13168599 A NO 13168599A NO 2700405 T3 NO2700405 T3 NO 2700405T3
Authority
NO
Norway
Application number
NO13168599A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2700405T3 publication Critical patent/NO2700405T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO13168599A 2008-05-29 2008-05-29 NO2700405T3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IT2008/000358 WO2009144755A1 (fr) 2008-05-29 2008-05-29 Virus herpès simplex (hsv) de tropisme modifié, utilisations et procédé de préparation
EP08789969.6A EP2293804B1 (fr) 2008-05-29 2008-05-29 Virus herpès simplex (hsv) de tropisme modifié, utilisations et procédé de préparation
EP13168599.2A EP2700405B1 (fr) 2008-05-29 2008-05-29 Virus de l'herpès simplex (hsv) avec tropisme modifié, utilisations et procédé de préparation associé

Publications (1)

Publication Number Publication Date
NO2700405T3 true NO2700405T3 (fr) 2018-09-01

Family

ID=40032777

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13168599A NO2700405T3 (fr) 2008-05-29 2008-05-29

Country Status (11)

Country Link
US (2) US9157071B2 (fr)
EP (2) EP2700405B1 (fr)
JP (1) JP5683455B2 (fr)
AU (1) AU2008357065B2 (fr)
DK (2) DK2293804T3 (fr)
ES (2) ES2425489T3 (fr)
HU (1) HUE037311T2 (fr)
NO (1) NO2700405T3 (fr)
PL (2) PL2293804T3 (fr)
PT (2) PT2293804E (fr)
WO (1) WO2009144755A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130749A2 (fr) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification de mutations dans les glycoprotéines d'enveloppe de virus herpès simplex qui permettent ou augmentent le reciblage de vecteur vers de nouveaux récepteurs non-hsv
BR112016009465A8 (pt) 2013-10-28 2018-01-30 Univ Pittsburgh Commonwealth Sys Higher Education vetor de hsv oncolítico.
WO2020142677A1 (fr) * 2019-01-03 2020-07-09 Albert Einstein College Of Medicine Transfert passif d'immunité au moyen de vecteurs de vaccin du virus de l'herpès simplex 2 (hsv -2) recombinant
EP3256570B1 (fr) 2015-02-11 2021-03-31 Alma Mater Studiorum -Universita' di Bologna Virus de l'herpès reciblé avec une fusion de glycoprotéine h
KR20180136435A (ko) 2016-01-27 2018-12-24 온코루스, 인크. 종양 살상형 바이러스 벡터 및 그의 용도
KR20190015544A (ko) * 2016-06-09 2019-02-13 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐 변형된 당단백질 d를 갖는 헤르페스 바이러스
WO2017211945A1 (fr) 2016-06-09 2017-12-14 Alma Mater Studiorum Universita Di Bologna Virus de l'herpès à glycoprotéine h modifiée pour la propagation dans une cellule
EP3469070B1 (fr) 2016-06-09 2021-08-04 Alma Mater Studiorum - Università di Bologna Virus de l'herpès comprenant une glycoprotéine b modifiée
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
US11612625B2 (en) 2017-07-26 2023-03-28 Oncorus, Inc. Oncolytic viral vectors and uses thereof
WO2019044925A1 (fr) * 2017-08-30 2019-03-07 Ｋｍバイオロジクス株式会社 Protéine hsv gd modifiée et vaccin la contenant
EP3731850A4 (fr) 2017-12-29 2021-12-01 Oncorus, Inc. Administration par un virus oncolytique de polypeptides thérapeutiques
CA3103374A1 (fr) * 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions et procedes d'administration d'anticorps
EP3887529A4 (fr) * 2018-11-28 2022-08-31 The Brigham & Women's Hospital, Inc. Virus de type 1 du virus de l'herpès simplex oncolytique fusogène régulable de nouvelle génération et méthodes d'utilisation
WO2021101796A1 (fr) * 2019-11-18 2021-05-27 The Brigham And Women's Hospital, Inc. Virus de l'herpès simplex de type 1 oncolytique fusogène régulable de nouvelle génération à codons optimisés et méthodes d'utilisation
KR102311895B1 (ko) * 2020-06-12 2021-10-14 주식회사 젠셀메드 재표적화를 위한 변형된 당단백질 gH를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도
CN112501137B (zh) * 2020-11-11 2023-10-20 深圳先进技术研究院 一种神经环路标记系统
EP4334439A1 (fr) * 2021-05-05 2024-03-13 Janssen Biotech, Inc. Reciblage universel du virus hsv oncolytique
CN113969287B (zh) * 2021-10-22 2024-05-28 中国科学院深圳先进技术研究院 重组单纯疱疹病毒的亲和筛选细胞系及其构建方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282721C (fr) 1984-06-04 1991-04-09 Bernard Roizman Virus de l'herpes simplex utilise comme vecteur
CA2279547A1 (fr) 1997-01-31 1998-08-06 University Of Rochester Proteines de fusion d'anticorps chimeriques utilisees pour induire et stimuler une reponse immunitaire antitumorale
US6080399A (en) 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2002069232A2 (fr) 2001-02-19 2002-09-06 Merck Patent Gmbh Procede d'identification d'epitopes de lymphocytes t et utilisation dans la preparation de molecules a immunogenicite reduite
EP1390069A1 (fr) 2001-05-30 2004-02-25 Cornell Research Foundation, Inc. Proteines de fusion endopeptidase/anticorps anti-psma servant au traitement du cancer
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
US20040115688A1 (en) 2002-04-19 2004-06-17 Cheung Irene Y. Detection of gd2 synthase mrna and uses thereof
US20070243170A1 (en) * 2002-10-07 2007-10-18 The University Of Chicago Targeting of Herpes Simplex Virus to Specific Receptors
EP1549339B1 (fr) 2002-10-07 2019-06-05 University Of Chicago Ciblage du virus de l'herpes simplex sur des recepteurs specifiques
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
JP5219819B2 (ja) 2005-10-21 2013-06-26 カタリスト・バイオサイエンシーズ・インコーポレイテッド 補体活性化を阻害する修飾プロテアーゼ
US20080038224A1 (en) 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
EP2423307A1 (fr) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Polypeptides du facteur IV à coagulation modifiée et leur utilisation pour le traitement
GB0714578D0 (en) * 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses

Also Published As

Publication number Publication date
EP2700405A1 (fr) 2014-02-26
US9744199B2 (en) 2017-08-29
US20110318268A1 (en) 2011-12-29
AU2008357065A1 (en) 2009-12-03
WO2009144755A1 (fr) 2009-12-03
JP2011522532A (ja) 2011-08-04
US9157071B2 (en) 2015-10-13
EP2293804A1 (fr) 2011-03-16
DK2700405T3 (en) 2018-05-22
ES2425489T3 (es) 2013-10-15
EP2293804B1 (fr) 2013-05-22
AU2008357065B2 (en) 2013-07-25
PT2700405T (pt) 2018-05-02
PL2293804T3 (pl) 2014-03-31
JP5683455B2 (ja) 2015-03-11
PT2293804E (pt) 2013-08-29
EP2700405B1 (fr) 2018-04-04
US20160074448A1 (en) 2016-03-17
HUE037311T2 (hu) 2018-08-28
DK2293804T3 (da) 2013-08-26
PL2700405T3 (pl) 2018-08-31
ES2667622T3 (es) 2018-05-11

Similar Documents

Publication Publication Date Title
BRPI0909040A2 (fr)
BRPI0908549B8 (fr)
BRPI0917525A2 (fr)
BRPI0907698A2 (fr)
BRPI0923734A2 (fr)
BRPI0912727A2 (fr)
BRPI0908285A2 (fr)
BRPI0910485A2 (fr)
BRPI0914750A2 (fr)
BRPI0915616A2 (fr)
BRPI0908120A2 (fr)
BRPI0912462A2 (fr)
BRPI0916284A2 (fr)
BRPI0913605A2 (fr)
BRPI0911617A2 (fr)
BRPI0914852A2 (fr)
BRPI0909508A2 (fr)
BRPI0910572A2 (fr)
CH2347250H2 (fr)
BRPI0914820A2 (fr)
BRPI0923127A (fr)
BRPI0923137A2 (fr)
CL47313B1 (fr)
CN300870818S (zh) 多媒体音箱导风管(甲盾f400)
CN300885598S (zh) 手套(--28)